retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing 𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿

Many patients with obesity are now managing their condition with a primarily pharmacological approach

doi: 10.1056/NEJMoa2403347 35 ArmstrongMJGauntPAithalGPBartonDHullDParkerRet al

Sources Baxter, S.M

3 While effective, this method can be inconvenient for many patients and may result in lower adherence compared to oral medications

Expected weight loss with the -enatides is only around 34 pounds, which is far less than with -glutides

Adults who have a body mass index (BMI) of at least 30 or who have a BMI between 27 and 30 as well as at least one weight-related health condition, such as heart disease, high cholesterol, or high blood pressure, are eligible for a prescription in consultation with their doctor